Novartis (NVS) Stock Price, News & Analysis

Company Overview

Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel, Switzerland. As one of the world’s leading healthcare firms, Novartis engages in the research, development, manufacturing and marketing of a broad portfolio of innovative medicines. Its core business is organized into two main divisions: Innovative Medicines, which focuses on patented prescription drugs in areas such as oncology, immunology, neuroscience and ophthalmology; and Sandoz, a global leader in generic pharmaceuticals and biosimilars.

Within its Innovative Medicines division, Novartis has developed several blockbuster treatments, including Gleevec (imatinib) for certain cancers, Cosentyx for immunological disorders, and Entresto for heart failure. The Sandoz unit supplies a wide range of affordable generic drugs across key therapeutic areas and invests in biosimilar versions of complex biologics. Together, these divisions support a lifecycle approach from early‐stage discovery and clinical development to global commercialization.

Novartis was formed in 1996 through the merger of Ciba-Geigy and Sandoz Laboratories, combining a long legacy of pharmaceutical and chemical research. This fusion created a diversified healthcare company with deep roots dating back to the 19th century. In February 2018, Vas Narasimhan, M.D., succeeded as Chief Executive Officer, ushering in a strategic focus on digital innovation and precision medicine.

Operating in more than 140 countries, Novartis maintains research facilities, manufacturing sites and commercial offices across North America, Europe, Asia Pacific and Latin America. The company collaborates with academic institutions, biotechnology firms and public health organizations to advance treatments for both common and rare diseases worldwide.

Key Stats

• Today's Range: $130.60 to $132.21
• 50-Day Range: $119.34 to $132.41
• 52-Week Range: $96.06 to $133.55
• Volume: 1.38 million shs
• Average Volume: 1.58 million shs
• Market Capitalization: $278.38 billion
• P/E Ratio: 19.18
• Dividend Yield: 1.97%
• Price Target: $120.33
• Consensus Rating: Hold

Novartis Stock Analysis - MarketRank™

Novartis scored higher than 51% of companies evaluated by MarketBeat, and ranked 533rd out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Hold

Consensus Rating

Novartis has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on 2 buy ratings, 4 hold ratings, and 3 sell ratings.

Downside Risk

Novartis has a consensus price target of $120.33, representing about 8.7% downside from its current price of $131.78.

Amount of Analyst Coverage

Novartis has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 4.26%

Earnings Growth

Earnings for Novartis are expected to grow by 4.26% in the coming year, from $8.45 to $8.81 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Novartis is 19.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 43.36.

Price to Earnings Ratio vs. Sector

The P/E ratio of Novartis is 19.18, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.48.

Price to Earnings Growth Ratio

Novartis has a PEG Ratio of 1.82. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Novartis has a P/B Ratio of 6.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.23% of the float of Novartis has been sold short.

Short Interest Ratio / Days to Cover

Novartis has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novartis has recently increased by 1.87%, indicating that investor sentiment is decreasing.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Novartis pays a meaningful dividend of 1.98%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Novartis does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Novartis is 37.85%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Novartis will have a dividend payout ratio of 29.51% next year. This indicates that Novartis will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.23% of the float of Novartis has been sold short.

Short Interest Ratio / Days to Cover

Novartis has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novartis has recently increased by 1.87%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.20

News Sentiment

Novartis has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 26 news articles for Novartis this week, compared to 23 articles on an average week.

Search Interest

19 people have searched for NVS on MarketBeat in the last 30 days. This is an increase of 12% compared to the previous 30 days.

MarketBeat Follows

10 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Novartis insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.01% of the stock of Novartis is held by insiders.

Percentage Held by Institutions

Only 13.12% of the stock of Novartis is held by institutions.

NVS Stock Analysis - Frequently Asked Questions

How have NVS shares performed this year?

Novartis' stock was trading at $97.31 on January 1st, 2025. Since then, NVS shares have increased by 35.4% and is now trading at $131.7810.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) announced its quarterly earnings data on Thursday, July, 17th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.04. The business's quarterly revenue was up 12.3% compared to the same quarter last year.
Read the conference call transcript.

Does Novartis have any subsidiaries?

Novartis subsidiaries include Gyroscope Therapeutics, Arctos Medical, Cellerys, Cadent Therapeutics, Vedere Bio, Vedere Bio ll, Amblyotech, and more.

Who are Novartis' major shareholders?

Novartis' top institutional shareholders include Douglas Lane & Associates LLC (0.01%), Allspring Global Investments Holdings LLC (0.01%), Euro Pacific Asset Management LLC and Ethic Inc..

How do I buy shares of Novartis?

Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Novartis investors own include BlackRock (BLK), Broadcom (AVGO), UnitedHealth Group (UNH), ServiceNow (NOW), Humana (HUM), TotalEnergies (TTE) and American Water Works (AWK).

Company Calendar

• Last Earnings: 7/17/2025
• Today: 10/21/2025
• Next Earnings (Estimated): 10/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:NVS
• CIK: 1114448
• Web: www.novartis.com
• Phone: (161) 324-1111
• Fax: 41-61-324-7826
• Employees: 75,883
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Novartis: $120.33
• High Price Target: $123.00
• Low Price Target: $118.00
• Potential Upside/Downside: -8.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.10
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.87
• Trailing P/E Ratio: 19.18
• Forward P/E Ratio: 15.60
• P/E Growth: 1.82
• Net Income: $11.94 billion
• Net Margins: 25.64%
• Pretax Margin: 29.30%
• Return on Equity: 41.08%
• Return on Assets: 16.83%

Debt

• Debt-to-Equity Ratio: 0.53
• Current Ratio: 0.82
• Quick Ratio: 0.62

Sales & Book Value

• Annual Sales: $50.32 billion
• Price / Sales: 5.53
• Cash Flow: $10.73 per share
• Price / Cash Flow: 12.28
• Book Value: $21.59 per share
• Price / Book: 6.10

Miscellaneous

• Outstanding Shares: 2,112,420,000
• Free Float: 2,112,211,000
• Market Cap: $278.38 billion
• Optionable: Optionable
• Beta: 0.64